Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

GSK’s Exdensur Receives UK Approval: A Breakthrough IL‑5Rα Therapy for Asthma and Nasal Polyps

GSK’s new drug Exdensur (depemokimab) gets UK approval, proving it reduces asthma and nasal‑polyp symptoms by targeting IL‑5Rα with a twice‑yearly shot.

Dr. Michael Chen

17/12/2025, 07:47

4 minutes to read

How Eli Lilly’s Weight‑Loss Pipeline Is Driving Investor Confidence and Growth

Explore Eli Lilly’s obesity strategy: proven sales of Mounjaro & Saxenda plus breakthrough Retatrutide data showing 17.5% weight loss—what this means for investors and future growth.

Dr. Michael Chen

16/12/2025, 15:00

4 minutes to read

Sanofi’s $1.7B Dren Bio Deal & Tolibrutinib Setback: What Investors Need to Know

Sanofi partners with Dren Bio for up to $1.7 billion to expand antibody‑based autoimmune therapies, while its tolebrutinib MS trial falls short, reshaping its pipeline and investor outlook.

Dr. Michael Chen

16/12/2025, 10:11

4 minutes to read

Qiagen NV: Stable Life‑Sciences Growth Through Sample‑Processing Leadership

Qiagen’s sample‑to‑insight solutions power precision medicine, offering stable growth for investors while boosting clinical trials and regulatory approvals.

Dr. Michael Chen

16/12/2025, 06:52

3 minutes to read

Alnylam Joins Nasdaq‑100, Boosting Visibility for RNAi Gene‑Silencing Breakthroughs

Alnylam’s Nasdaq‑100 debut boosts its RNAi drug pipeline and investor visibility, highlighting breakthroughs in liver, eye, and CNS gene‑silencing therapies.

Dr. Michael Chen

15/12/2025, 21:12

4 minutes to read

Insmed Joins Nasdaq‑100, Boosting Investor Interest in Its Gene Therapy & ADC Pipeline

Insmed joins the Nasdaq‑100, boosting visibility and investor interest while advancing breakthrough gene therapy for cystic fibrosis and ADC for hepatocellular carcinoma.

Dr. Michael Chen

14/12/2025, 17:03

4 minutes to read

Insmed’s Brinsupri Breakthrough: Strong Phase IIb Results Fuel Investor Optimism

Insmed’s breakthrough PARP‑inhibitor Brinsupri shows 32% response rates and improved quality‑of‑life in platinum‑resistant ovarian cancer, sparking new investor interest and a fast‑track FDA review.

Dr. Michael Chen

13/12/2025, 13:00

4 minutes to read

Waters Corp. Surges with Analyst Upgrades, Strong RSI & New LC‑MS Innovation

Waters Corp. gains “Outperform” upgrades and bullish RSI as its LC‑MS innovations, FDA clearance, and strategic biopharma partnership boost investor confidence.

Dr. Michael Chen

13/12/2025, 10:40

3 minutes to read

Merck’s RSV Antibody Pipeline Boosts Investor Confidence Amid Regulatory Scrutiny

Merck’s RSV antibody pipeline shows 68% risk reduction in high‑risk infants, but FDA safety reviews may delay launch—investors weigh clinical promise against regulatory risk.

Dr. Michael Chen

13/12/2025, 05:12

3 minutes to read

Waters Corp Stock Surges: Technical Momentum, Analyst Upgrades & Strong Pipeline Drive Positive Outlook

Waters Corp’s stock hits new highs—boosted by a strong pipeline, 12% revenue growth, and an “Outperform” upgrade, positioning it ahead of peers in analytical tech.

Dr. Michael Chen

12/12/2025, 18:27

3 minutes to read

Older articles